Kornimate/medical-research-clean huggingface dataset:
aml patients bearing flt3 mutations based on peripheral blast clearance

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation

Summary: prospective, multi-center, interventional, randomized, open clinical trial for the treatment of acute myeloid leukemia with flt3 mutations customized upon the prognostic parameter pbc


Eligibility criteria:
inclusion criteria: 1. patients with de novo aml, untreated, newly diagnosed, according to who 2016 criteria 2. presence of a mutation of flt3 gene, either itd and/or tkd 3. adequate availability of diagnostic biologic material for full cytological, cytogenetic, genetic and immunophenotypic disease characterization according to eln criteria. 4. presence of morphologically identifiable blasts on peripheral blood at diagnosis 5. presence of a leukemia-associated aberrant immune-phenotype (laip) as assessed by mfc (multiparametric flow cytometry) at diagnosis 6. age between 18 and 65 years, included 7. ecog performance status 0-2 or disease-related reversible ecog 3 score following adequate supportive care. 8. signed written informed consent according to ich/eu/gcp and national local laws exclusion criteria: 1. diagnosis of acute promyelocytic leukemia 2. diagnosis of aml with t(8;21)(q22:q22)/runx1-runx1t1 and t(16;16)(p13:q22) or inversion of chromosome 16 (16)(p13q22)/cbfb-myh11; in case of suspicion of cbf-related aml due to morphological and/or immunophenotypic features, specific fish or molecular testing is strongly recommended in accordance with who criteria3,157 3. patients with lvef less than 45% (by echocardiogram or muga) 4. pre-existing, uncontrolled pathology such as heart failure (congestive/ischaemic, acute myocardial infarction within the post 3 months, untreatable arrhythmias, nyha classes iii and iv), sever liver disease with total bilirubin ≥2,5 x uln and/or alt\>3 uln (unless attributable to aml), acute or chronic pancreatitis, kidney function impairment with serum creatinine ≥2,5 (unless attributable to aml) and severe neuropsychiatric disorder that impairs the patient's ability to understand and sign the informed consent or to cope with the intended treatment plan. for altered liver, pancreas and kidney function tests, eligibility criteria can be reassessed at 24-96 hours, following the institution of adequate supportive measures. 5. uncontrolled bacterial or fungal infections 6. qtc \>470 msec on screening ecg (fridericia's formula) 7. a history of cancer that is not in remission phase following surgery and/or chemotherapy and/or radiotherapy with life expectancy \< 1 year. 8. pregnancy declared by the patient herself. a pregnancy test is performed at diagnosis and, if applicable, before allogeneic hsct . female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from enrollment through 4 months after the end of treatment.
caffeine consumption in glaucoma patients and healthy subjects

Conditions: Glaucoma, Primary Open Angle

Summary: caffeine is the most widely consumed drinking nutrient in the world. caffeine effects various organs and the vascular system. it decreases ocular blood flow due to vasoconstriction.

ingestion of caffeine in glaucoma patients and healthy subjects may decrease peripapillary and macular blood flow in the back of the eye. the primary objective of this study is to assess the acute changes in peripapillary and macular blood flow before and after an intake of oral caffeine (200 milligram tablet) in glaucoma patients and healthy subjects by using optical coherence tomography angiography (octa) scans. this novel imaging tool creates three-dimensional angiograms to assesses signal changes caused by flowing blood cells in a non-invasive angiogram scan. blood flow is shown as vessel density measured in percentage.

Eligibility criteria:
inclusion criteria: * age 18 to 90 years * diagnosis of primary open angle glaucoma (mild, moderate and advanced) * healthy subjects with no eye disease exclusion criteria: * diseases, ophthalmic or systemic, that are likely to affect octa results * greater than moderate cataract * nystagmus * inability to look at target * macular degeneration other than mild drusen or pigmentary changes * diabetic retinopathy * neovascular glaucoma or non-glaucoma optic neuropathies * current macular edema, prior laser to retina, inflammatory retinopathy or choroidopathy * keratoconus, corneal ectasia, central corneal scarring * rheumatologic diseases or raynaud's phenomena * pregnant and lactating women * mental illness or alcohol addiction * pre-existing bladder symptoms, cardiac disease or sleep disorder * refractive spherical diopter greater than 5 or cylinder greater than 3 * possible tolerance to caffeine (drinking more than 1 cup coffee per day).

Keywords: primary open angle glaucoma (poag) optical coherence tomography angiography (octa) caffeine macular blood flow peripapillary blood flow
the effect of sodium fluoride application on the prevention of radiation caries in npc patients

Conditions: Sodium Fluoride

Summary: to evaluate the efficacy of sodium fluoride to preventing radiation caries for patients with nasopharyngeal carcinoma receiving radiotherapy.


Eligibility criteria:
inclusion criteria: * a. patients with histologically confirmed non-keratinizing npc (including differentiated type and undifferentiated type, world health organization \[who\] ii or iii). b. original clinical staged as ii-iva (according to the 8th ajcc edition) c. male or female who are not pregnant. d. no evidence of distant metastasis (m0). e. age between 18-60 years. f. wbc≥4×109/l, plt≥100×109/l, hgb≥90g/l. g. normal liver function test: alanine aminotransferase (alt), aspartate aminotransferase (ast) \<1.5×upper limit of normal (uln) concomitant with alkaline phosphatase (alp) ≤2.5×uln, and bilirubin ≤uln. i. with normal renal function test (creatinine clearance rate≥60 ml/min or creatinine\< 1.5×uln. j. the eastern cooperative oncology group (ecog) performance status less or equal to 1. k. patients must be informed of the investigational nature of this study and give written informed consent. l. patients receive nasopharyngeal and neck radiotherapy. m. after pre-radiotherapy oral examination, no less than 2 functional teeth in any 1/6 segment of the mouth. exclusion criteria: * a. with clinical stage of i and ivb (according to the 8 th ajcc edition). b. patients with tumor recurrence or distant metastasis. c. prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer. d. history of previous radiotherapy (except for non-melanomatous skin cancers outside intended rt treatment volume). e. prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes. f. pregnancy or lactation (consider pregnancy test in women of child-bearing age and emphasize effective contraception during the treatment period). g. fewer than 2 functional teeth in any 1/6 segment of the mouth after pre-radiotherapy scaling. h. lesions of infection in the oral cavity at baseline, severe gingivitis (gingival index = 3, i.e., severe inflammation of the gums, marked redness, swelling or ulceration of the gums, and a tendency to bleed automatically). i. age \ 60. j. any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, acute exacerbation of chronic obstructive pulmonary disease or other respiratory illness requiring admission to hospital, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×uln), and mental disturbance.

Keywords: nasopharyngeal carcinoma sodium fluoride radiation caries
effect of oleic acid on inflammation markers and blood lipid metabolites: a randomised, double-blind, crossover study

Conditions: Inflammation

Summary: rationale: the effect of positional distribution of dietary fatty acids on markers of inflammation and blood lipids metabolites on diets containing fatty acids such as oleic acid that are associated with reduced risk of cardiovascular disease is not widely studied. hypothesis: there would be difference detected in the concentrations of markers of inflammation and blood lipid metabolites in human volunteers fed controlled diets. study design: a randomized, double-blind, crossover clinical trial that involves 41 healthy volunteers. the volunteers will be selected based on inclusion and exclusion criteria. they will consume controlled diets for 5 weeks that provides 15% of energy from protein, 30% of energy from fat, and 55% of energy from carbohydrates. volunteers will be assigned to each test diets which is cooked with novel olein, palm stearin or partially hydrogenated soybean oil in random order until all three diets has consumed by each person. main study parameters: ldl-cholesterol


Eligibility criteria:
inclusion criteria: * healthy and free from any disease and absence of family history for arteriosclerosis or hypertension * not on any medication or supplements or weight loss program * non smokers and alcoholics exclusion criteria: * having some health-related problems e.g fever, flu, allergy, chronic diseases * on some treatment or medication * smokers and alcoholics

Keywords: inflammation ldl oleic acid palmitic acid trans fatty acid c-reactive protein
bicalutamide in treatment of androgen receptor (ar) positive metastatic triple negative breast cancer

Conditions: Metastatic Triple Negative Breast Cancer

Summary: compare the efficacy of bicalutamide with conventional chemotherapy (treatment of physician's choice,tpc) in first-line treatment of ar positive metastatic triple negative breast

this is a phase iii,multi-center,prospective,randomized clinical trials. the objective compare the efficacy of bicalutamide with conventional chemotherapy (treatment of physician's choice,tpc) in first-line treatment of ar positive metastatic triple negative breast cancer.primary endpoint is 16-week clinical benefit rate (cbr).by centre randomized grouping bicalutamide (experimental group) or tpc (control group).

Eligibility criteria:
inclusion criteria: * age: 18-70 years old, female * eastern cooperative oncology group (ecog) 0 or 1 * confirmed by pathology or organizing cytology ar positive(ihc：≧10%)triple negative breast cancer * for the first time recurrence or newly diagnosed advanced breast cancer,disease-free survival time 12 months above * measurable disease per recist version 1.1,or immeasurably lesions bone metastasis * after recurrence has not received cancer treatment * life expectancy of at least 6 months * signed and dated an informed consent form exclusion criteria: * ecog score ≧2 * only brain metastasis or meningeal metastasis * receiving other anti-tumor treatment * heart,lung,liver,kidney,bone marrow,and other functions badness
effectiveness of the vasodilator test with revatio, made in patients with acute pulmonary hypertension

Conditions: Pulmonary Hypertension

Summary: the main objective is to validate the safety and efficacy of intravenous and oral sildenafil in the acute vasodilator test in patients with persistence of, at least, moderate pulmonary hypertension after valvular surgery successfully, with a correct left ventricular function and no valvular disease hemodynamically significant.


Eligibility criteria:
inclusion criteria: * patients clinically stable, at least 1 year after the completion of successful valve surgery, with persistent pulmonary artery systolic pressure\> 50 mmhg, * normal left ventricular function and no significant valvular disease in 2 separate doppler ultrasound studies at least 1 month. exclusion criteria: * patients with other cardiac and noncardiac diseases will be excluded.
study to assess hemodynamic effects, safety and tolerability of chimeric natriuretic peptide (cd-np) in patients with stabilized acute heart failure (ahf)

Conditions: Acute Decompensated Heart Failure

Summary: to access the efficacy of intravenous (iv) administration of cd-np on changes in cardiac output and wedge pressure in patients with stabilized acute heart failure


Eligibility criteria:
key inclusion criteria: * hospitalization for ahf * in need of hemodynamic monitoring key exclusion criteria: * administration of intravenous radiographic contrast agent within 7 days prior to screening or planned iv contrast media administration in the 4 days after screening or acute contrast-induced nephropathy at the time of screening * current or planned treatment with any iv therapies, including diuretics, vasodilators (including nesiritide), vasopressin antagonists, positive inotropic agents and vasopressors, or mechanical support * current or planned ultrafiltration, hemofiltration, or dialysis within 7 days of screening * significant pulmonary disease * known valvular heart disease * any organ transplant recipient or patient currently listed for transplant or admitted for any transplantation. * major surgery within 30 days of screening * other major disability or disease with expected survival less than 6 months. * major neurologic event, including cerebrovascular events, in the 60 days prior to screening * clinical diagnosis of acute coronary syndrome within 45 days of screening * troponin t ≥ 3 times the upper limit of normal at screening * significant arrhythmias * acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy * liver function abnormality * administration of an investigational drug or implantation of investigational device, or participation in another trial, within 30 days prior to screening

Keywords: adhf ahf hf
survey of adolescent living in vestmanland

Conditions: Alcohol Abuse; Criminalism; Depression

Summary: the interaction of mao-a genotype and psychosocial risk, in relation to male adolescent criminality the interaction of 5-httlpr genotype and psychosocial risk in relation to excessive adolescent alcohol consumption the interaction of 5-httlpr genotype and psychosocial risk in relation to depressive symptoms among adolescents the interaction of mao-a genotype and psychosocial risk, in relation to female adolescent criminality


Eligibility criteria:
inclusion criteria: all students present in school class during survey

Keywords: adolescent alcohol criminology genes environment mono amine oxidase serotonin social support
comparison of analgesic efficacy of penb block with ficb in post operative hip fracture patients

Conditions: Post-operative Pain Management; Hip Fracture Surgery

Summary: this study was done to evaluate two different interventions for postoperative pain control in patients undergoing hip surgeries. fifty patients, divided in two equal groups, were included in the study. patients in group p were given pericapsular nerve group (peng) block while those in group f were given fascia iliaca compartment block (ficb). pain score, using numeric rating scale as a measurement tool, was assessed at one, six, eighteen and twenty fours after the procedure as a primary outcome. total tramadol consumption in milligrams was recorded as a secondary outcome.


Eligibility criteria:
inclusion criteria: * surgical correction of fracture neck of femur under spinal anaesthesia exclusion criteria: * allergy to local anaesthetics * bleeding disorders * morbid obesity with bmi more than 35 * patients of chronic pain * drug addiction * psychiatric issues
evaluation of woulgan in diabetic foot ulcer

Conditions: Diabetic Foot Ulcers

Summary: the aim of the current study is to support the performance and safety of woulgan® in the treatment of diabetic foot ulcer in comparison with the commercially available hydrogel intrasite. healing and untoward medical events to be evaluated.


Eligibility criteria:
inclusion criteria: * type i or ii diabetes mellitus. * target ulcer area between 0.5 and 5 sqcm, and more than 4 weeks old. * ankle-brachial pressure index above 0.7. exclusion criteria: * ulcers due to non-diabetic etiology. * uncontrolled diabetes defined as hba1c above 70 mmol/mol and insufficient nutritional status. * ulcers older than 1 year. * any of gangrene, osteomyelitis, cellulitis, or charcot osteoarthropathy.
internet delivered self-help cbt for insomnia

Conditions: Insomnia

Summary: the object of this study is to determine variables associated with therapy-success of a cognitive behavioral self help intervention for insomnia. in this study all participants receive an online self-help cbt manual consisting of information (psycho-education) about sleep and cognitive-behavioural exercises. adult persons with insomnia will be invited via a popular scientific website to fill out online questionnaires. participants will be measured 4, 16, and 40 weeks after intervention with the same questionnaires.


Eligibility criteria:
inclusion criteria: * insomnia * access to the internet exclusion criteria: * alcohol or substance abuse * being suicidal * sleep apnea * schizophrenic or having a psychosis disorder

Keywords: insomnia intervention self-help internet
the association between herpes simplex viruses and autism

Conditions: Autism Spectrum Disorder

Summary: autism spectrum disorders are pervasive developmental disorders that include autistic disorder, asperger's disorder, and pervasive developmental disorder-not otherwise specified.they are characterized by stereotypic behaviors, variable deficits in language and social skills and a wide range of other behavioral problems. autism spectrum disorders manifest during childhood and at least thirty percent present with sudden clinical regression of development around three years of age.

over the last twenty years, there has been an impressive rise in autism spectrum disorders with current prevalence estimates being about one over one hundred children. herpes simplex virus encephalitis is the leading cause of sporadic, nonepidemic encephalitis in children and adults in the united states. it is an acute necrotizing infection generally involving the frontal and/or temporal cortex and the limbic system and, beyond the neonatal period, is almost always caused by herpes simplex virus type on. the etiology of autism is unknown; data suggest that autism results from multiple etiologies with both genetic and environmental contributions. one proposed etiology for autism is viral infection very early in development. the mechanism, by which viral infection may lead to autism, be it through direct infection of the central nervous system, through infection elsewhere in the body acting as a trigger for disease in the central nervous system, through alteration of the immune response of the mother or offspring, or through a combination of these, is not yet known. many encephalitic patients had temporal lobe involvement. autism results from neuropathology relating to the temporal lobes. they speculate the differences in the extent and neuropathologies of the temporal lobes contribute to the heterogeneity of autism. also, herpes viruses can induce a variety of proinflammatory cytokines during infections, along with elevated interferon in the brain during herpes simplex virus encephalitis.

Eligibility criteria:
inclusion criteria: 1. children suffering from autism spectrum disorders. 2. age between six months and five years exclusion criteria: 1. genetic disorders. 2. history of metabolic or neurodegenerative disease. 3. gross motor delay. 4. audiologic problems. 5. mental retardation. 6. other psychiatric problems.
en bloc turbt with collins loop vs conventional turbt

Conditions: Bladder Cancer; Bladder Neoplasm; Bladder Urothelial Carcinoma; Bladder Cancer Stage; Urothelial Carcinoma Recurrent

Summary: this is a prospective, randomized, randomized and single-blind study in patients diagnosed with primary bladder cv. patients diagnosed by cystoscopy of a bladder tumor and with indication for endoscopic surgical treatment, who meet the inclusion criteria, and who sign the informed consent (ic), will be randomized.

the main objective of the study is to assess the quality of the resection, defined as the presence of detrusor muscle in the resected tissue. the secondary objetives are: * compare the surgical time, hospital stay, urinary catheterization time and incidence of complications. * compare tumor recurrence after one year of follow up. * determine the number of re-turb as a consequence of the absence of muscle layer in the sample or artifacts (tx) * establish the incidence of conversions as a consequence of difficulties in the technique or intraoperative bleeding. * compare the degree of satisfaction of the surgeon

Eligibility criteria:
inclusion criteria: * \>18 years old. * polypoid / sessile primary tumor. * \< 3 tumors * tumor size 10 - 30 mm. exclusion criteria: * \> 4 tumors * size of the largest tumor \ 4 cm. * tumor located in the bladder dome. * no visualization of the ureteral meatus. * flat or in situ tumor. * non-urothelial tumors. * clotting disorder or treatment with oral anticoagulants.
a comparison of mri perfusion and fdg pet/ct to distinguish between radiation injury and tumor progression

Conditions: Brain Cancer

Summary: this study will examine if mri perfusion and pet/ct can tell growing tumor and radiation injury apart. mri perfusion looks at the blood vessels in the tumor. pet/ct looks if the tumor cells are actively growing. the investigators will do these two tests and see which one is better. patients will remain on study until the completion of either the mri perfusion or pet/ct that are within 12 weeks of each other. after one of these scans, the patient will have no active interventions and will be off study. optional: restriction spectrum imaging (rsi) sequence rsi sequence is an advanced way of looking at your brain. the scan allows doctors to see how water is moving within brain tumors or within brain cells. the extra sequence takes additional 4-5 minutes in the scanner. the rsi sequence is optional. the patient will only be asked to participate if the doctor believes that it will be helpful. off study: patients will remain on study until the completion of either the mri perfusion or pet/ct that are within 12 weeks of each other. after one of these scans, the patient will have no active interventions and will be off study. patients will obtain a standard of care brain mri scan about every 2-3 months. these mri scans will be used to track disease progression.


Eligibility criteria:
inclusion criteria: * pathological or clinical/radiological diagnosis of aneoplasm , either primary (e.g., malignant glioma) or secondary (metastasis from systemic malignancy) with a history of brain radiation therapy * completed fractionated radiation therapy (to 60 gy for high grade gliomas) or stereotactic radiosurgery or hypofractionated radiation therapy (e.g. for brain metastases, anaplastic meningiomas), without or with concurrent chemotherapy * new or increased enhancing brain lesion(s) or nonenhancing brain lesion(s) if receiving anti-angiogenic therapy, which is considered indeterminate for tumor progression vs. radiation injury by the neuroradiologist or clinician * patient and/or guardian is able to provide written informed consent prior to study registration * age ≥ 18 years old exclusion criteria: * claustrophobia * known allergic reaction to gd-dtpa * any contraindication to gadolinium intravenous contrast as per standard department of radiology contrast guidelines * any contraindication to mri (e.g., pacemaker, aneurysm clip, tissue expander). * pregnant or nursing female * unable to cooperate for mri and/or pet/ct

Keywords: brain tumor mri perfusion fdg pet/ct 12-067